

ACORDA THERAPEUTICS INC  
Form 8-K  
August 25, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **August 25, 2009**

**Acorda Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50513**  
(Commission  
File Number)

**13-3831168**  
(I.R.S. Employer  
Identification No.)

**15 Skyline Drive, Hawthorne, NY**  
(Address of principal executive offices)

**10532**  
(Zip Code)

Registrant's telephone number, including area code: **(914) 347-4300**

**Not Applicable**

Former name or former address, if changed since last report

## Edgar Filing: ACORDA THERAPEUTICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On August 25, 2009, Acorda Therapeutics, Inc. (the Registrant ) issued a press release announcing that the U.S. Food and Drug Administration s Peripheral and Central Nervous System Drugs Advisory Committee will review the Registrant s New Drug Application for Fampridine-SR on October 14, 2009. The Registrant also announced that is has received preliminary approval for the proposed trade name Amaya from the U.S. Food and Drug Administration.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated August 25, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

*August 25, 2009*

*By:*

*/s/ David Lawrence*

*Name: David Lawrence*

*Title: Chief Financial Officer*

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated August 25, 2009.